Emergent BioSolutions, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, April 21, 2021 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises Emergent BioSoutions, Inc. ("Emergent" or the "Company") (NYSE: EBS) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

The New York Times published an article on March 31, 2021 reporting on the accidental contamination of coronavirus vaccines developed by Johnson & Johnson and AstraZeneca PLC at an Emergent manufacturing plant in Baltimore. According to reporting by the Associated Press, this Emergent factory where the contamination occurred experienced a series of lapses, as observed in April 2020 by the U.S. Food and Drug Administration in April 2020. On April 1, 2021, Emergent's stock price fell $12.45 per share, or 13.4%, on this news, to close at $80.46 per share.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising